



50130

**Composition**

Leveron 500mg XR tablet: Each extended-release tablet contains Levetiracetam USP 500 mg.  
Leveron 750mg XR tablet: Each extended-release tablet contains Levetiracetam USP 750 mg.

**Pharmacokinetics:**

Bioavailability of Leveron XR tablets is similar to that of the immediate-release Leveron tablets. The pharmacokinetics (AUC and Cmax) were shown to be dose proportional after single dose administration of 1000 mg, 2000 mg, and 3000 mg extended-release levetiracetam. The time to peak plasma concentrations is about 3 hours longer with extended-release levetiracetam than with immediate-release tablets. Levetiracetam is not significantly protein-bound (less than 10% bound) and its volume of distribution is close to the volume of intracellular and extracellular water. Levetiracetam is not extensively metabolized in humans; about 24% of a dose is metabolized by hydroxylation to inactive metabolites. The plasma elimination half-life has been reported to be about 7 ± 1 hours in adults and children aged 12 years and over and is unaffected by either dose or repeated administration. Levetiracetam is eliminated from the systemic circulation by renal excretion as an unchanged drug which represents 66% of administered dose. Levetiracetam is distributed into breast milk.

**Indication:**

Levetiracetam XR is indicated as adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy.

**Dose and Administration**

For adults and adolescent patients, the recommended dosing for monotherapy and adjunctive therapy is the same as outlined below.  
*Adults and Adolescents 12 Years of Age and Older Weighing 50 kg or More*  
Initiate treatment with a dose of 1000 mg once daily. The once daily dosage may be adjusted in increments of 1000 mg every 2 weeks to a maximum recommended daily dose of 3000 mg/day once daily.

**Administration**

Leveron XR is administered once daily. Leveron XR tablets should be swallowed whole. The tablets should not be chewed, broken, or crushed.  
*Dosage Adjustments in Adult Patients with Renal Impairment*  
Levetiracetam dosing must be individualized according to the patient's renal function status. Recommended dosage adjustments for adults are shown in the Table.

Dosage Adjustment Regimen for Adult Patients with Renal Impairment

Group	Creatinine Clearance (mL/min/1.73m <sup>2</sup> )	Dosage (mg)	Frequency
Normal	> 80	1000 to 3000	Every 24 hours
Mild	50 – 80	1000 to 2000	Every 24 hours
Moderate	30 – 50	500 to 1500	Every 24 hours
Severe	< 30	500 to 1000	Every 24 hours

**Contra-indications:**

Leveron XR is contraindicated in patients with hypersensitivity to levetiracetam. Reactions have included anaphylaxis and angioedema.

**Precautions:**

Patients should be advised that Levetiracetam may cause dizziness and somnolence. Accordingly, patients should be advised not to drive or operate

machinery or engage in other hazardous activities until they have gained sufficient experience on Levetiracetam to gauge whether it adversely affects their performance of these activities. Patients should be advised that Levetiracetam may cause changes in behavior (e.g. aggression, agitation, anger, anxiety, apathy, depression, hostility and irritability) and in rare cases patients may experience psychotic symptoms and/or suicidal ideation.

**Side-Effect:**

Nausea, vomiting, dyspepsia, diarrhea, abdominal pain, anorexia, weight changes; cough; drowsiness, asthenia, amnesia, ataxia, seizures, dizziness, headache, tremor, hyperkinesia, depression, emotional lability, insomnia, anxiety, impaired attention, aggression, irritability; thrombocytopenia; myalgia; visual disturbances; pruritis, rash; also reported pancreatitis, hepatic dysfunction, confusion, psychosis, hallucinations, suicidal ideation, paraesthesia, leucopenia, pancytopenia and alopecia.

**Pregnancy and Lactation:**

There are no adequate data from the use of Levetiracetam in pregnant women. Levetiracetam should not be used during pregnancy unless clearly necessary. Discontinuation of antiepileptic treatments may be harmful to the mother and the fetus. Levetiracetam is excreted in human breast milk. Therefore, breast-feeding is not recommended.

**Drug Interactions:**

Phenytoin: Levetiracetam (3000mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy. Pharmacokinetics of levetiracetam were also not affected by phenytoin.  
Valproate: Levetiracetam (1500mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers. Valproate 500mg twice daily did not modify the rate or extent of levetiracetam absorption or its plasma clearance or urinary excretion.  
Potential drug interaction between levetiracetam and other AEDS (carbamazepine, gabapentin, lamotrigine, Phenobarbital, phenytoin, primidone, and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies. These data indicate that levetiracetam does not influence plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of levetiracetam.

**Over dosage:**

Leveron XR overdose are expected to be similar to those seen with immediate-release Leveron tablets. The highest known dose of levetiracetam received in the clinical development program was 6000mg/day. Other than drowsiness, there were no adverse events in the few known cases of overdose in clinical trials. Cases of somnolence, agitation, aggression, aggression, depressed level of consciousness, respiratory depression, and coma were observed with of levetiracetam overdoses in post marketing use. If indicated, elimination of unabsorbed drug should be attempted by emesis or gastric lavage; usual precautions should be observed to maintain airway.

**Storage Condition:**

Store in a cool temperature (not exceeding 25°C) and dry place, protected from light. Keep out of the reach of children.

**Commercial Pack:**

Leveron 500mg XR tablet: 2x10's tablet in alu alu blister pack  
Leveron 750mg XR tablet: 2x6's tablet in alu alu blister pack

Manufactured by:



Synovia Pharma PLC., Station Road, Tongi, Gazipur.  
A Subsidiary of BEXIMCO PHARMACEUTICALS LTD.

3021000365

Legend of Packaging Artwork	
Name of Printed D/S	Leveron Tablet D/S
Oracle Code	3021000365
Synovia Version No	02
Artwork generation date	21.04.2024
Dimensions	L-100 mm in X W-250 mm (Both Side)
Minimum font size	8 pt
Color Ref	Pantone process black ■ Pantone 2347 C ■
Artwork Prepared By	In House (Anowar Hossain)
Change Control Ref No	
Artwork Checked By	Quality Control
	Change Control Coordinator
	Market Regulatory
	Marketing